At Element, our mission has always been to enable researchers to do “smarter science”. This means creating tools that optimize for time and resources, while maximizing the insights scientists obtain from their experiments.
Thats why we call AVITI24™ the first truly intelligent multiomics system; a descriptor rooted in the system’s capacity to work with scientists to advance their research at the pace and scale modern innovation necessitates.
Our recent paper, titled “High-Throughput Multiomics Profiling of Model Systems Using the AVITI24 Platform,” highlights AVITI24’s propensity to do just that.
Traditional methods of omic analysis all suffer from the same common drawbacks: they only let scientists look at one aspect of cells at a time - either their shape, their RNA, or their proteins.
But AVITI24 changes this paradigm. As illustrated in this paper, the system enables scientists to analyze all of these aspects simultaneously in the same cells with single cell and spatial resolution, giving researchers a comprehensive view of cellular activity.
"It’s no longer enough to look at one data type in isolation," explains Tyler Lopez, lead scientist on the AVITI24 paper, and Element’s Associate Director of Biochemistry. "Without integrating protein, RNA, and cell morphology, critical insights are easily overlooked. You can have RNA responses without corresponding protein responses, or protein responses on a completely different timescale. The ability to move seamlessly between these data types is where the future of cellular analysis is heading, and what we are delivering with this system.”
In areas like cancer research, understanding exactly how cells respond to drugs is crucial. Cancer cells are incredibly adaptive, often finding ways to survive treatments that should kill them. This recent study demonstrates how AVITI24 reveals these survival mechanisms with unprecedented detail.
In our research, we exposed different cancer cell types to TNFα, a molecule that typically triggers cell death. Using AVITI24, we demonstrated that rather than failing to detect the signal, cancer cells actively rewire their internal signaling pathways to neutralize the threat.
"We made this system highly customizable from day one, a difficult but essential task. For example, our custom kit allows up to 88 antibodies. The sheer scale and flexibility we've created opens up entirely new possibilities for researchers across different fields."
For drug developers, this means faster, more accurate screening of potential treatments. For cancer researchers, it offers unprecedented insights into treatment resistance mechanisms.
By creating detailed maps of cellular responses over time, AVITI24 can help scientists identify precisely where drug interventions might be most effective. This could significantly accelerate the development of more targeted cancer therapies that outsmart resistance mechanisms.
Our scientists' next steps involve using machine learning to extract even deeper insights from these rich datasets, potentially revolutionizing how we approach drug discovery.
Interested in learning more? Read the full paper.